Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks - Pimecrolimus and Epidermal Barrier Functio
- Conditions
- Atopic Dermatitis
- Registration Number
- EUCTR2004-004824-11-DE
- Lead Sponsor
- niversitätshautklinik Kiel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Adults with atopic dermatitis of mild to moderate severity.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Patients who are pregnant, nursing, immunocompromised or presenting signs of skin atrophy.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Examination of the treatment mechanism of pimecrolimus on epidermal barrier function in atopic dermatitis.;Secondary Objective: Examination of epidermal cell proliferation and cell differentiation.;Primary end point(s): Improvement/change in values for transepidermal water loss in the skin (TEWL).
- Secondary Outcome Measures
Name Time Method